AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24442330 — intervention group
Group type: EXPERIMENTAL
Intervention: EEG analysis using permutation entropy (PeEn)
Number of subjects: 15
Study 24442330 — intervention group
Group type: EXPERIMENTAL
Intervention: EEG sequences evaluated for stationarity
Number of subjects: 15
Study 22369339 — intervention group
Group type: EXPERIMENTAL
Intervention: Competitive exergame condition
Number of subjects: 54
Study 22369339 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooperative exergame condition
Number of subjects: 54
Study 22369339 — intervention group
Group type: COMPARATOR
Intervention: No-play control group
Number of subjects: 54
Study 22369339 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss during the intervention
Number of subjects: 54
Study 20678895 — intervention group
Group type: EXPERIMENTAL
Intervention: Macmillan Approach to Weight and Eating (MAWE)
Number of subjects: 50
Study 20678895 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 50
Study 17685676 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2 (medicine ball training)
Number of subjects: 49
Study 17685676 — intervention group
Group type: COMPARATOR
Intervention: Group 1 (control group with no medicine ball training)
Number of subjects: 49
Study 17685676 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Group 1 and Group 2)
Number of subjects: 49
Study 16168282 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents (SES)
Number of subjects: 141
Study 16168282 — intervention group
Group type: COMPARATOR
Intervention: Bare-metal stents (BMS)
Number of subjects: 141
Study 12060327 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotational technique
Number of subjects: 145
Study 12060327 — intervention group
Group type: COMPARATOR
Intervention: Standard 'nonrotational' technique
Number of subjects: 145
Study 10535235 — intervention group
Group type: EXPERIMENTAL
Intervention: CRAFT approach (community reinforcement and family training)
Number of subjects: 130
Study 10535235 — intervention group
Group type: COMPARATOR
Intervention: Al‐Anon facilitation therapy
Number of subjects: 130
Study 10535235 — intervention group
Group type: COMPARATOR
Intervention: Johnson Institute intervention
Number of subjects: 130
Study 10535235 — intervention group
Group type: EXPERIMENTAL
Intervention: All three approaches
Number of subjects: 130
Study 10535235 — intervention group
Group type: EXPERIMENTAL
Intervention: CRAFT approach
Number of subjects: 130
Study 7768073 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolcapone 200 mg and higher
Number of subjects: 48
Study 7768073 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolcapone (5 to 800 mg)
Number of subjects: 48
Study 7768073 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolcapone
Number of subjects: 48
Study 7768073 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-O-methylmetabolite of tolcapone
Number of subjects: 48
Study 2382605 — intervention group
Group type: EXPERIMENTAL
Intervention: Urokinase (3.0 million units over 30 minutes intravenously) with maximal antianginal therapy and intravenous heparin
Number of subjects: 31
Study 393732 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolic acid (MPA)
Number of subjects: 21
Study 393732 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 393732 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolic acid (MPA) after placebo
Number of subjects: 21
Study 31898874 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive Lifestyle Intervention (ILI)
Number of subjects: 5145
Study 31898874 — intervention group
Group type: COMPARATOR
Intervention: Diabetes support and education (Control)
Number of subjects: 5145
Study 30953665 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal insulin (160 IU)
Number of subjects: 0
Study 30953665 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 0
Study 29191800 — intervention group
Group type: EXPERIMENTAL
Intervention: Reminders-presented (high frequency, 14 reminders over 28 days)
Number of subjects: 64
Study 29191800 — intervention group
Group type: EXPERIMENTAL
Intervention: Reminders-presented (low frequency, 7 reminders over 28 days)
Number of subjects: 64
Study 29191800 — intervention group
Group type: COMPARATOR
Intervention: Reminders-absent
Number of subjects: 64
Study 29191800 — intervention group
Group type: EXPERIMENTAL
Intervention: Acknowledgment of reminders
Number of subjects: 64
Study 29191800 — intervention group
Group type: EXPERIMENTAL
Intervention: Time since acknowledging receipt of a reminder
Number of subjects: 64
Study 24638884 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication treatment for ADHD
Number of subjects: 66
Study 24638884 — intervention group
Group type: COMPARATOR
Intervention: Behavior therapy (BT)
Number of subjects: 66
Study 24638884 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment (behavior therapy and/or stimulant medication)
Number of subjects: 66
Study 23450464 — intervention group
Group type: EXPERIMENTAL
Intervention: Gait speed measured with the 6‐m or 10‐m timed walking test
Number of subjects: 153
Study 23450464 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariate model including gait speed and fear of falling
Number of subjects: 153
Study 21592234 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfuzosin 10mg daily for 4 weeks and dologesic (paracetamol+dextropropoxyphene, four tablets daily on demand) for 2 weeks
Number of subjects: 67
Study 21592234 — intervention group
Group type: COMPARATOR
Intervention: Control group received dologesic for 2 weeks only
Number of subjects: 67
Study 19779491 — intervention group
Group type: EXPERIMENTAL
Intervention: 160 mg valsartan (V group, n=22)
Number of subjects: 43
Study 19779491 — intervention group
Group type: COMPARATOR
Intervention: 80 mg valsartan plus low-dose trichlormethiazide (1 mg) (V+D group, n=21)
Number of subjects: 43
Study 17159818 — intervention group
Group type: EXPERIMENTAL
Intervention: (18)FDG PET
Number of subjects: 42
Study 12629458 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 min run
Number of subjects: 16
Study 12629458 — intervention group
Group type: EXPERIMENTAL
Intervention: static stretch
Number of subjects: 16
Study 12629458 — intervention group
Group type: EXPERIMENTAL
Intervention: run + stretch
Number of subjects: 16
Study 12629458 — intervention group
Group type: EXPERIMENTAL
Intervention: run + stretch + practice jumps
Number of subjects: 16
Study 12629458 — intervention group
Group type: COMPARATOR
Intervention: control
Number of subjects: 16
Study 10717350 — intervention group
Group type: EXPERIMENTAL
Intervention: DTP acellular vaccines
Number of subjects: 2163
Study 10717350 — intervention group
Group type: EXPERIMENTAL
Intervention: DTP whole cell vaccine
Number of subjects: 2163
Study 10717350 — intervention group
Group type: COMPARATOR
Intervention: DT vaccine
Number of subjects: 2163
Study 10717350 — intervention group
Group type: EXPERIMENTAL
Intervention: 3, 5, 12 month schedule
Number of subjects: 2163
Study 10717350 — intervention group
Group type: EXPERIMENTAL
Intervention: 2, 4, 6 month schedule
Number of subjects: 2163
Study 10717350 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-5 years after the third dose
Number of subjects: 2163
Study 8741950 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone maintenance (50 mg PO daily)
Number of subjects: 22
Study 8741950 — intervention group
Group type: COMPARATOR
Intervention: Cocaine challenge doses (0, 12.5, 25, and 50 mg IV)
Number of subjects: 22
Study 1392359 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin-to-skin with the mother
Number of subjects: 50
Study 1392359 — intervention group
Group type: COMPARATOR
Intervention: Separated in a cot
Number of subjects: 50
Study 3903789 — intervention group
Group type: EXPERIMENTAL
Intervention: Flupenthixol (0.5 to 2 mg a day)
Number of subjects: 113
Study 3903789 — intervention group
Group type: COMPARATOR
Intervention: Diazepam (2.5 to 10 mg a day)
Number of subjects: 113
Study 3903789 — intervention group
Group type: COMPARATOR
Intervention: Sulpiride (100 to 200 mg a day)
Number of subjects: 113
Study 30792342 — intervention group
Group type: EXPERIMENTAL
Intervention: Interdisciplinary model of care (smoking cessation support, home medicines review, home-based pulmonary rehabilitation)
Number of subjects: 272
Study 30792342 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 272
Study 29086478 — intervention group
Group type: EXPERIMENTAL
Intervention: High flavonoid apple (HFA)
Number of subjects: 30
Study 29086478 — intervention group
Group type: COMPARATOR
Intervention: Low flavonoid apple (LFA)
Number of subjects: 30
Study 26555785 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical ivermectin
Number of subjects: 62
Study 26555785 — intervention group
Group type: COMPARATOR
Intervention: Oral ivermectin
Number of subjects: 62
Study 25637602 — intervention group
Group type: EXPERIMENTAL
Intervention: metoprolol (β1-selective)
Number of subjects: 47
Study 25637602 — intervention group
Group type: EXPERIMENTAL
Intervention: metoprolol+doxazosin (β1/α1)
Number of subjects: 47
Study 25637602 — intervention group
Group type: EXPERIMENTAL
Intervention: carvedilol (β1/β2/α1)
Number of subjects: 47
Study 23918000 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic Urticaria Patient Daily Diary (eUPDD)
Number of subjects: 91
Study 23918000 — intervention group
Group type: COMPARATOR
Intervention: Paper Urticaria Patient Daily Diary (UPDD)
Number of subjects: 91
Study 23918000 — intervention group
Group type: EXPERIMENTAL
Intervention: Urticaria Activity Score (sum of 'itch severity' and 'number of hives')
Number of subjects: 91
Study 21757939 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g paracetamol i.v.
Number of subjects: 60
Study 21757939 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg diclofenac sodium i.m.
Number of subjects: 60
Study 21757939 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg lornoxicam i.v.
Number of subjects: 60
Study 18835043 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole (15‐30 mg/day)
Number of subjects: 480
Study 18835043 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium (900‐1500 mg/day)
Number of subjects: 480
Study 18835043 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 480
Study 16962720 — intervention group
Group type: EXPERIMENTAL
Intervention: Single breath of 35% CO(2)
Number of subjects: 14
Study 16962720 — intervention group
Group type: COMPARATOR
Intervention: Air inhalation
Number of subjects: 14
Study 16962720 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute tryptophan depletion (ATD)
Number of subjects: 14
Study 16962720 — intervention group
Group type: EXPERIMENTAL
Intervention: Single breath of 35% CO(2) and ATD combined
Number of subjects: 14
Study 12531752 — intervention group
Group type: EXPERIMENTAL
Intervention: Semitendinosus tendon graft
Number of subjects: 71
Study 12531752 — intervention group
Group type: COMPARATOR
Intervention: Bone-patellar tendon-bone graft
Number of subjects: 71
Study 12531752 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 71
Study 10645045 — intervention group
Group type: EXPERIMENTAL
Intervention: abciximab
Number of subjects: 42
Study 10645045 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 42
Study 9513824 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-week course of amoxicillin and tinidazole for index children and siblings younger than 18; 2-week course of Colloidal Bismuth Subcytrate and tinidazole for parents and siblings over 18
Number of subjects: 47
Study 9513824 — intervention group
Group type: COMPARATOR
Intervention: Control group (children with dyspepsia and Helicobacter pylori gastritis whose infected family contacts were not treated)
Number of subjects: 47
Study 7699213 — intervention group
Group type: EXPERIMENTAL
Intervention: LH‐RH analogs treatment for Group 1 patients (P.A.H. < -1 SDS) for 2 years
Number of subjects: 26
Study 7699213 — intervention group
Group type: COMPARATOR
Intervention: No treatment for Group 2 patients (P.A.H. > -1 SDS) for 2 years
Number of subjects: 26
Study 2646988 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily change of povidone-iodine dressing
Number of subjects: 83
Study 2646988 — intervention group
Group type: COMPARATOR
Intervention: Original dressing unchanged (Control)
Number of subjects: 83
Study 29869460 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 83
Study 29869460 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 83
Study 28199710 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT‐I + antidepressant (AD; escitalopram)
Number of subjects: 107
Study 28199710 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT‐I + placebo pill
Number of subjects: 107
Study 28199710 — intervention group
Group type: COMPARATOR
Intervention: AD + 4‐session sleep hygiene control (SH)
Number of subjects: 107
Study 28199710 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 107
Study 25053587 — intervention group
Group type: EXPERIMENTAL
Intervention: GIP
Number of subjects: 10
Study 25053587 — intervention group
Group type: COMPARATOR
Intervention: GLP-1
Number of subjects: 10
Study 25053587 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 10
Study 24913347 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy (MBCT)
Number of subjects: 139
Study 22440074 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative mood with 'as many as can' stop rule
Number of subjects: 0
Study 22440074 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive mood with 'feel like continuing' stop rule
Number of subjects: 0
Study 22440074 — intervention group
Group type: COMPARATOR
Intervention: Discrete negative moods
Number of subjects: 0
Study 20406273 — intervention group
Group type: EXPERIMENTAL
Intervention: Home visits advising mothers about healthy feeding practices (monthly advice up to 6 months and then at 8, 10, and 12 months)
Number of subjects: 500
Study 20406273 — intervention group
Group type: EXPERIMENTAL
Intervention: Home visits advising mothers about healthy feeding practices
Number of subjects: 500
Study 20406273 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 500
Study 18636308 — intervention group
Group type: EXPERIMENTAL
Intervention: Group self-management education
Number of subjects: 20
Study 15930443 — intervention group
Group type: EXPERIMENTAL
Intervention: Fortified dairy product containing eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), oleic acid, folic acid, and vitamins A, B‐6, D, and E, 500 mL/d
Number of subjects: 60
Study 15930443 — intervention group
Group type: COMPARATOR
Intervention: Semiskimmed milk with added vitamins A and D, 500 mL/d
Number of subjects: 60
Study 12885705 — intervention group
Group type: EXPERIMENTAL
Intervention: 18 g essential amino acids (EAA group)
Number of subjects: 14
Study 12885705 — intervention group
Group type: COMPARATOR
Intervention: 40 g balanced amino acids (BAA group)
Number of subjects: 14
Study 10400089 — intervention group
Group type: EXPERIMENTAL
Intervention: Temazepam (10 mg)
Number of subjects: 10
Study 10400089 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 9086127 — intervention group
Group type: EXPERIMENTAL
Intervention: New cell culture-derived vaccinia virus vaccine administered intradermally
Number of subjects: 91
Study 9086127 — intervention group
Group type: EXPERIMENTAL
Intervention: New cell culture-derived vaccinia virus vaccine administered intramuscularly
Number of subjects: 91
Study 9086127 — intervention group
Group type: COMPARATOR
Intervention: Licensed vaccinia vaccine administered by scarification
Number of subjects: 91
Study 8457081 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticlopidine, 500 mg/day
Number of subjects: 16
Study 8457081 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 3091205 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 40
Study 3091205 — intervention group
Group type: COMPARATOR
Intervention: Halothane
Number of subjects: 40
Study 30946276 — intervention group
Group type: EXPERIMENTAL
Intervention: Velocity-Based Training (VBT)
Number of subjects: 16
Study 30946276 — intervention group
Group type: COMPARATOR
Intervention: Percentage-Based Training (PBT)
Number of subjects: 16
Study 29361981 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative Brief Electrical Stimulation (BES) applied to the spinal accessory nerve (SAN) for 60 minutes at 20 Hz, 3-5 V, 0.1 msec balanced biphasic pulses.
Number of subjects: 54
Study 29361981 — intervention group
Group type: COMPARATOR
Intervention: No stimulation (NS) as control group.
Number of subjects: 54
Study 29361981 — intervention group
Group type: EXPERIMENTAL
Intervention: BES in patients with Level IIb + V neck dissections.
Number of subjects: 54
Study 27049086 — intervention group
Group type: EXPERIMENTAL
Intervention: Wuzhi capsule (one capsule in the morning and evening for 3 weeks)
Number of subjects: 60
Study 27049086 — intervention group
Group type: COMPARATOR
Intervention: Control group (no Wuzhi capsule)
Number of subjects: 60
Study 24906133 — intervention group
Group type: COMPARATOR
Intervention: Intravenous propranolol (1 mg)
Number of subjects: 20
Study 24906133 — intervention group
Group type: COMPARATOR
Intervention: Oral propranolol (40 mg)
Number of subjects: 20
Study 24906133 — intervention group
Group type: COMPARATOR
Intervention: Total serum bile acids
Number of subjects: 20
Study 24906133 — intervention group
Group type: COMPARATOR
Intervention: Correlation between SBA concentration and propranolol oral AUC0-∞
Number of subjects: 20
Study 22969845 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin B12 + Goshajinkigan treatment (Group B)
Number of subjects: 29
Study 22969845 — intervention group
Group type: COMPARATOR
Intervention: Vitamin B12 treatment (Group A)
Number of subjects: 29
Study 20594220 — intervention group
Group type: EXPERIMENTAL
Intervention: Mosapride 15 mg/day
Number of subjects: 22
Study 18315714 — intervention group
Group type: EXPERIMENTAL
Intervention: Semen samples from young men in Hamburg
Number of subjects: 791
Study 18315714 — intervention group
Group type: EXPERIMENTAL
Intervention: Semen samples from young men in Leipzig
Number of subjects: 791
Study 18315714 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined semen samples from Hamburg and Leipzig
Number of subjects: 791
Study 18315714 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of motile spermatozoa
Number of subjects: 791
Study 15742266 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative oral antibiotic treatment
Number of subjects: 280
Study 15742266 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotonic saline irrigation
Number of subjects: 280
Study 15742266 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative topical antibiotic drops
Number of subjects: 280
Study 15742266 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 280
Study 12093661 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitomycin-C (0.05 mg/ml) applied topically to the filtering bleb on days 1, 2, and 3 after surgery (postoperative application)
Number of subjects: 50
Study 12093661 — intervention group
Group type: COMPARATOR
Intervention: Mitomycin-C (0.2 mg/ml) applied by means of a sponge during surgery (intraoperative application)
Number of subjects: 50
Study 10503682 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized budesonide (2 mg 8 hourly)
Number of subjects: 46
Study 10503682 — intervention group
Group type: COMPARATOR
Intervention: Oral prednisolone (2 mg/kg at entry and again at 24 h)
Number of subjects: 46
Study 8879982 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg of standardized ginseng extract Ginsana G 115
Number of subjects: 227
Study 8879982 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 227
Study 8879982 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 227
Study 8378107 — intervention group
Group type: EXPERIMENTAL
Intervention: TENS
Number of subjects: 42
Study 8378107 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo-TENS
Number of subjects: 42
Study 3005152 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 micrograms clonidine
Number of subjects: 8
Study 3005152 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 28060527 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrinsic religiosity
Number of subjects: 2322
Study 28060527 — intervention group
Group type: COMPARATOR
Intervention: Depression
Number of subjects: 2322
Study 27040801 — intervention group
Group type: EXPERIMENTAL
Intervention: 13 G vacuum-assisted biopsy (VAB)
Number of subjects: 81
Study 27040801 — intervention group
Group type: COMPARATOR
Intervention: 14 G core needle biopsy (CNB)
Number of subjects: 81
Study 27040801 — intervention group
Group type: COMPARATOR
Intervention: Comparison of repeat procedure willingness
Number of subjects: 81
Study 27040801 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnostic yield
Number of subjects: 81
Study 25267748 — intervention group
Group type: EXPERIMENTAL
Intervention: p16 positive expression in non-OPSCC
Number of subjects: 322
Study 25267748 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV ISH positive status in non-OPSCC
Number of subjects: 322
Study 25267748 — intervention group
Group type: EXPERIMENTAL
Intervention: p16 expression for progression-free survival (PFS)
Number of subjects: 322
Study 25267748 — intervention group
Group type: EXPERIMENTAL
Intervention: p16 expression for overall survival (OS)
Number of subjects: 322
Study 25267748 — intervention group
Group type: COMPARATOR
Intervention: p16 positive OPSCC vs p16 positive non-OPSCC
Number of subjects: 322
Study 25267748 — intervention group
Group type: COMPARATOR
Intervention: p16 negative OPSCC vs p16 negative non-OPSCC
Number of subjects: 322
Study 22541306 — intervention group
Group type: EXPERIMENTAL
Intervention: Supported Employment (SE)
Number of subjects: 201
Study 22541306 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU-IS)
Number of subjects: 201
Study 22541306 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU-OS)
Number of subjects: 201
Study 20930100 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy (CBT) consisting of up to ten 1-hour sessions within 6 months
Number of subjects: 220
Study 20930100 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief nursing intervention (BNI) consisting of two 1-hour sessions, 3 months apart
Number of subjects: 220
Study 20930100 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 220
Study 17684525 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily vitamin D3 supplement plus 500 mg calcium (CaD group)
Number of subjects: 102